Vaxdigm (CEO Kim Seong-jae) announced on the 1st that it had been selected for the Ministry of SMEs and Startups' scale-up support program, "Post-TIPS." Post-TIPS is a program that supports the subsequent growth of startups with outstanding R&D achievements among TIPS graduates.
Through this project, Baxdigm plans to accelerate the development of an avian influenza vaccine using its "CHAPERNA" platform, a rapid development platform for E. coli-based genetically recombinant synthetic antigen vaccines. The CHAPERNA platform enables the efficient and stable production of complex protein antigens, and its economical and rapid process reduces development and mass production time and costs. Furthermore, the produced vaccine does not require ultra-low temperature freezing, increasing distribution and storage efficiency, enabling a stable supply to low- and middle-income countries (LMICs).
Kim Sung-jae, CEO of Baxdime, said, “The selection as Post-TIPS will accelerate the development of next-generation vaccines and the establishment of a production system,” and added, “Along with securing Korea’s vaccine sovereignty, we will also contribute to solving health problems in countries with low vaccine accessibility through international organizations such as WHO, UNICEF, PAHO, and GAVI.”
To advance this project, a non-clinical trial drug production process will be established, preclinical efficacy testing will be conducted, and funding for clinical trials, WHO PQ certification, and international bidding will be secured through Series B investment. Baxdime has already secured KRW 2.7 billion in Series A funding, bringing its total investment to KRW 9.8 billion.
Baxdime CEO Kim Seong-jae said, “We are securing practical momentum for vaccine commercialization and entry into the global market by expanding domestic and international technology transfer, CDMO collaboration, and networks with overseas NGOs and government agencies.”
- See more related articles
You must be logged in to post a comment.